Sunday, August 18, 2019

BerGenBio ASA: Results for the Second Quarter and First Half 2019

- Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy - Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical...



from PR Newswire: https://ift.tt/2TJOwSJ

No comments:

Post a Comment